Game-Changing Solution for Heart Inflammation? | David Elsley – Cardiol Therapeutics

FULL DISCLOSURE: This is sponsored content for Cardiol Therapeutics.

In this interview with David Elsley, President and CEO of Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL), we explore the company’s innovative approach to treating inflammatory heart conditions. Cardiol’s lead product, CardiolRx™, is an oral therapy targeting recurrent pericarditis and acute myocarditis – debilitating heart conditions that currently lack effective treatment options.

Elsley discusses their promising Phase 2 trial results presented at the American Heart Association, showing sustained pain reduction and decreased inflammation markers. He explains how their ultra-high-dose, pharmaceutically manufactured formulation differs from standard CBD products, and outlines key upcoming catalysts including Phase 2/3 trial results expected in early 2025 that could accelerate their path to market under FDA’s orphan drug designation.

READ: Cardiol To Advance CardiolRx To Phase III Trial Following Positive Results


FULL DISCLOSURE: Cardiol Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is long the equity of Cardiol Therapeutics. The author has been compensated to cover Cardiol Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Epic Gold Outlines 150,700 Indicated Ounces at 2.26 G/T in Updated Benoist Resource

Related News

A Medical Breakthrough the Market Overlooked | David Elsley – Cardiol Therapeutics

In this interview David Elsley, CEO of Cardiol Therapeutics (NASDAQ: CRDL) (TSXV: CRDL), shares some...
Monday, August 18, 2025, 03:53:00 PM

Cardiol Therapeutics Releases Positive Topline Results From Phase II Clinical Trial

Cardiol Therapeutics (TSX: CRDL) (NYSE: CRDL) has released topline results from their phase two ARCHER...
Thursday, August 7, 2025, 11:28:24 AM

Cardiol Enters Into Supply Agreement With Shoppers Drug Mart

Cardiol Therapeutics Inc. (TSX: CRDL) has entered into a supplier agreement with Medical Cannabis by...

Wednesday, March 18, 2020, 03:27:03 PM

A Heart Disease Cure For Pericarditis? Phase 3 Trial Advances | David Elsley – Cardiol Therapeutics

Discover the major breakthrough at Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) as CEO David Elsley...
Saturday, April 26, 2025, 11:38:00 AM

Fixing Heart Disease Tied to Sudden Death in Young People | David Elsley – Cardiol Therapeutics

In this conversation with David Elsley, President and CEO of Cardiol Therapeutics Inc. (NASDAQ: CRDL)...
Sunday, April 19, 2026, 09:24:00 AM